0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > CD2

CD2

Brief Information

Name:T-cell surface antigen CD2
Target Synonym:T11,T-Cell Surface Antigen CD2,LFA-2,CD2 Antigens,CD2,LFA-3 Receptor,CD2 Molecule,Rosette Receptor,SRBC,CD2 Antigen,CD2 Antigen (P50), Sheep Red Blood Cell Receptor,T-Cell Surface Antigen T11/Leu-5,Lymphocyte-Function Antigen-2,Erythrocyte Receptor
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

CD2-H5258-BLI
 CD2 BLI

Loaded Human CD2, Fc Tag (Cat. No. CD2-H5258) on Protein A Biosensor, can bind Human CD58, His Tag (Cat. No. LF3-H5225) with an affinity constant of 2.3 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

CD2-H5226-BLI
 CD2 BLI

Loaded bind Human CD58, Fc Tag (Cat. No. LF3-H5256) on Protein A Biosensor, can bind Human CD2, His Tag (Cat. No. CD2-H5226) with an affinity constant of 0.49 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name

CD2,SRBC,LFA-2,T11

Background

T-cell surface antigen CD2 is also known as Erythrocyte receptor, LFA-2, LFA-3 receptor, Rosette receptor, T-cell surface antigen T11/Leu-5 and SRBC, is a single-pass type I  membrane protein found on the surface of T cells and natural killer (NK) cells. CD2 is a member of the immunoglobulin superfamily. CD2 / SRBC contains 1 Ig-like C2-type (immunoglobulin-like) domain and 1 Ig-like V-type (immunoglobulin-like) domain. CD2 / SRBC interacts with other adhesion molecules, such as lymphocyte function-associated antigen-3 (LFA-3 / CD58) in humans, or CD48 in rodents, which are expressed on the surfaces of other cells. In addition to its adhesive properties, CD2 also acts as a co-stimulatory molecule on T and NK cells. CD2 is a specific marker for T cells and NK cells, and can therefore be used in immunohistochemistry to identify the presence of such cells in tissue sections.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Siplizumab MEDI-507; TCD-601 Phase 2 Clinical Catholic University Of Louvain, Itb-Med Llc Rejection of renal transplantation; Diabetes Mellitus, Type 1; Leukemia; Renal Insufficiency; Rejection of liver transplantation; Neoplasms; Myelodysplastic Syndromes; Kidney Diseases; Graft vs Host Disease; Multiple Myeloma; Psoriasis; Lymphoma, T-Cell; Hidradenitis Suppurativa; Lymphoma; Anemia, Sickle Cell; Kidney Failure, Chronic Details
Alefacept LFA-3-TIP; LFA-3(92)IgG; BG-9273; BG-9712; ASP-0485 Phase 1 Clinical Astellas Pharma Inc Diabetes Mellitus, Type 1; Graft vs Host Disease; Psoriasis; Anemia, Aplastic; Lymphoma Details
SBT-11-5301 SBT115301 Phase 1 Clinical Sonoma Biotherapeutics Inc Autoimmune Diseases Details
PIT-565 PIT-565 Phase 1 Clinical Novartis Pharma Ag Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lupus Erythematosus, Systemic; Leukemia, Myeloid, Acute Details
Siplizumab MEDI-507; TCD-601 Phase 2 Clinical Catholic University Of Louvain, Itb-Med Llc Rejection of renal transplantation; Diabetes Mellitus, Type 1; Leukemia; Renal Insufficiency; Rejection of liver transplantation; Neoplasms; Myelodysplastic Syndromes; Kidney Diseases; Graft vs Host Disease; Multiple Myeloma; Psoriasis; Lymphoma, T-Cell; Hidradenitis Suppurativa; Lymphoma; Anemia, Sickle Cell; Kidney Failure, Chronic Details
Alefacept LFA-3-TIP; LFA-3(92)IgG; BG-9273; BG-9712; ASP-0485 Phase 1 Clinical Astellas Pharma Inc Diabetes Mellitus, Type 1; Graft vs Host Disease; Psoriasis; Anemia, Aplastic; Lymphoma Details
SBT-11-5301 SBT115301 Phase 1 Clinical Sonoma Biotherapeutics Inc Autoimmune Diseases Details
PIT-565 PIT-565 Phase 1 Clinical Novartis Pharma Ag Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lupus Erythematosus, Systemic; Leukemia, Myeloid, Acute Details

This web search service is supported by Google Inc.

totop

Nachricht schicken